Introduction
Epstein-Barr virus (EBV) is a widely spread human gammaherpesvirus, whose prevalence exceeds 95% of the adult human population. 1 After the primary infection, as EBV establishes persistence in B lymphocytes, it can be detected both in lymphoid tissue and peripheral blood. 2, 3 In immunosuppressed patients, the virus-host imbalance favors EBV reactivation which in turn induces lymphoproliferation. 4 Therefore, it has been proposed that these benign proliferations may become malignant lymphomas if they are not well controlled by the host immune system, although this is a rare event. 5 EBV has been associated with a variety of malignancies due to its detection in malignant cells. [6] [7] [8] [9] The EBV-associated tumors described in the HIV-infected population include non-Hodgkin lymphomas, Hodgkin lymphomas, Burkitt lymphomas, and smooth muscle malignancies. The strength of association differs, being about 100% in cases of primary brain lymphomas, which appear when patients are profoundly immunosuppressed; in this sense, they are essentially analogous to post-transplant lymphoproliferative disorder (PTLD) lesions of the transplant group. 4, 10 In the transplant population a relationship was found between circulating EBV load and PTLD. 11, 12 Moreover, higher circulating EBV DNA levels precede PTLD diagnosis, which allows for early therapeutic intervention in patients with rising levels of EBV, thus preventing the establishment of this life-threatening entity; also other reports noted decreased EBV load with successful therapy. [13] [14] [15] The EBV load has been much less studied in the HIVinfected group than in transplant individuals. As in transplant patients, frequent reactivation of EBV infection has been observed in HIV-infected individuals, reflected by increased EBV-specific antibody titers, [16] [17] [18] and more recently, high numbers of circulating copies of EBV. 19, 20 However, controversy persists regarding the usefulness of measuring EBV levels in AIDS patients in relation to lymphoma risk, diagnosis, and management. [21] [22] [23] [24] [25] The semi-quantitative PCR (SQ-PCR) method used to measure EBV load was developed in our laboratory to monitor transplant patients and in fact, its usefulness was demonstrated for the detection of differences in circulating levels of EBV DNA. Although different strategies such as competitive methods or real time PCR have proven to yield the best results, the SQ-PCR method is, for us, more affordable. 26 The aim of our study was to analyze the EBV load in different HIV infection stages and its relation with primary brain lymphoma.
Materials and methods

Study population
One hundred and seventy-two HIV-infected patients from the ''J.F. Muñiz'' Infectious Diseases Hospital (Buenos Aires, Argentina) were included in this study. All of them were receiving antiretroviral therapy, with the exception of asymptomatic HIV-infected patients with CD4+ T cells counts above 350/mm 3 . Mean patient age was 26 years (range 16-61 years), male/female ratio was 2:3, and they were grouped according to the 1993 CDC classification, 27 as follows: 62 asymptomatic HIV-infected patients (group A), 30 HIV progressors (group B), 73 AIDS patients (group C), and seven AIDS patients with a diagnosis of primary central nervous system lymphoma (PCNSL) (group C-BL). They were all typed as nonHodgkin lymphoma according to the WHO classification.
Twenty-six blood donors (group BD), who were healthy EBV carriers from the same hospital, were also included. They were all negative for the usual blood bank tested infections; mean age of this group was 34 years (range 19-50 years).
All the study population showed previous evidence of EBV infection (presence of IgG antibodies against viral capsid antigen (VCA) detected by indirect immune fluorescence assay). All participants gave their informed consent for inclusion in this study. A local ethics committee approved all procedures.
Samples
EDTA anti-coagulated blood samples were collected and peripheral blood mononuclear cells (PBMC) separated from plasma after a Ficoll-Hypaque gradient centrifugation (Lymphoprep, GIBCO). Fresh brain biopsy tissue (BB) and in some cases cerebrospinal fluid (CSF) were obtained from C-BL patients. All samples were stored at À20 8C until used. Paraffin embedded lymphoma tissue was examined with in situ hybridization (ISH).
DNA extraction
DNA from PBMC, plasma, and BB was extracted with proteinase K lysis buffer and purified by a phenol-chloroform procedure. 28 DNA from CSF was extracted as previously described. 29 
EBV quantification
Viral load was determined applying a semi-quantitative method as we have previously described. 26 This method was developed to detect high EBV loads, i.e., levels above those found in healthy carriers (latent state). Briefly, a nested PCR was performed, which amplifies a fragment of 122 bp from the BWRF1 gene. For PBMC, DNA equivalent to 10 5 cells (366 ng) and its serial four-fold dilutions were amplified until limiting dilution was reached. The amplified products were run in a 2% agarose gel stained with ethidium bromide and the end point was converted into viral copies/10 5 PBMC by multiplying the sensitivity of the assay (1-16 copies) by the reciprocal of the limiting dilution (RLD). We subsequently applied Circulating EBV is mainly cell-associated in the HIV-infected population. Neither PBMC-EBV nor plasma-EBV loads would be useful to diagnose brain lymphoma in AIDS patients. # 2006 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved. the method to plasma samples; the intra-and inter-assay variation result was the same as for PBMC specimens, i.e., AE one four-fold dilution (data not shown). Thus, we considered the same sensitivity and reproducibility as was described for PBMC samples. For plasma specimens, DNA obtained from 30 mL (similar to the volume associated with 10 5 PBMC) 14 and its serial four-fold dilutions were amplified and quantified as mentioned. The presence of PCR inhibitors was determined when EBV load was <1 copy/10 5 PBMC or 30 mL of plasma as follows: (A) Inhibitors in DNA extracted from PBMC samples were determined by amplifying the human b-globin gene using primer set PCO4 and GH20 to amplify a 268 bp DNA fragment as described by Bauer et al. 30 (B) Inhibitors in DNA extracted from plasma samples were tested by spiking around 125 ng of DNA obtained from human fibroblasts onto DNA extracted from 30 mL of plasma, and then the human b-globin gene was amplified as described above ( Figure 1 ).
EBV qualitative detection
For EBV DNA qualitative determination, DNA extracted from 50 ul of CSF or about 300 ng of DNA BB were amplified by the same nested PCR applied for quantification, using different cycling conditions in the first round: 3 min at 94 8C, and forty 1-min cycles at 94 8C, 30 s at 58 8C, 1 min at 72 8C; and 10 min at 72 8C.
EBERs detection
To determine EBV association with PCNSL, a commercial in situ hybridization (ISH) method that detects EBV-encoded RNA (EBERs) transcripts was applied on paraffin-embedded lymphoma tissue sections mounted onto silane-coated glass RNA controls (Dakocytomation, Glostrup, Denmark), followed by its detection with a PNA ISH detection kit (Dakocytomation, Glostrup, Denmark), were used according to manufacturers' instructions.
Number of CD4+ and CD8+ lymphocytes
These were determined by standard flow cytometry techniques. 
Statistical analyses
Results
EBV load and clinical HIV state
HIV-infected individuals were found to exhibit a significantly higher detection rate and increased levels of circulating EBV DNA compared to blood donors ( p < 0.05). Similar results were obtained when comparing each HIV clinical set without lymphoma to the BD group (Figure 2) . Also, no statistically significant differences ( p > 0.05) in EBV detection and EBV load were found between groups A, B, and C. The C-BL group was found to have a significantly ( p < 0.05) lower circulating EBV rate and levels compared to groups A and B.
EBV load and CD4+ T cells
EBV detection was similar in all groups with CD4+ Tcell counts higher than 50/mm 3 ( p > 0.05), and significantly higher than in patients with less than 50 CD4+ T cells/mm 3 ( p < 0.05). When analyzing EBV levels, we found no statistically significant differences between groups with more than 50 CD4+ T cells/mm 3 . On the other hand, circulating EBV levels in patients with less than 50 CD4+ T cells/mm 3 were significantly ( p < 0.05) lower than in those with CD4+ Tcells counts EBV in HIV-infected patients and primary brain lymphoma between 50 and 500/mm 3 . Figure 3 illustrates the results of EBV quantification as regards the number of CD4+ T lymphocytes.
EBV load and CD8+ T cells
No correlation was found between EBV circulating levels and the number of CD8+ T cells in the HIV-infected population studied (data not shown).
Relation between PBMC-and plasma-EBV load
Plasma-EBV load was measured in about 20 patients of each HIV clinical set: A, B, and C (n = 55), and in all seven C-BL cases. The criterion for plasma selection was that all PBMC-EBV load ranks were represented. Therefore, when analyzing EBV DNA in different peripheral blood compartments of all HIV groups, we observed no correlation between PBMC and plasma levels (Figure 4) . Also, EBV load was lower in plasma samples than in PBMC for most HIV positive cases without lymphoma; only two patients (from groups A and C) had similar circulating EBV DNA copies in both samples. Two of the seven HIV-infected patients with PCNSL had higher EBV levels in plasma than in PBMC (patients 1 and 3, Table 1 ).
Discussion
In this project, we noted that in HIV-infected patients EBV in peripheral blood is higher than in healthy individuals. Thus, higher EBV DNA detection rates were found in PBMC of HIVinfected patients compared to healthy individuals, in agreement with the report by Ling et al. 20 Contrary to this finding, Dehee et al. described a similar EBV positivity rate in HIVinfected patients and asymptomatic HIV negative volunteers. 19 In the latter case, the percentage of EBV DNA detection in HIV negative individuals was strikingly high compared to other reports. 20, 21, 29, 31 These differences could be due to the control groups, the methodological strategies, or the sensitivity of the techniques. Also, increased PBMC-EBV load was found in all the clinical HIV infection categories (groups A, B, and C), indicating that the imbalance between EBV infection and the host immunologic control starts early in the course of HIV clinical infection, and continues as the infection progresses. In a prospective study, Piriou et al.
proved that PBMC-EBV load increases rapidly following HIV seroconversion, and remains high even five years later, both in asymptomatic carriers and AIDS progressors. 24 Since CD4+ T cell depletion is the immunologic hallmark of HIV-related disease progress, 32, 33 we also analyzed the relation of circulating EBV levels and the progress of immunological deterioration, according to CD4+ T cell counts by the CDC classification. In agreement with reports by Dehee et al., 19 and Ling et al., 20 when the number of CD4+ T cells is greater than 50/mm 3 , higher levels of circulating PBMC-EBV are seen in HIV-infected patients, compared to healthy carriers. This situation may reflect the loss of EBV infection control due to progressive immunosuppression, similar to the situation widely described for transplant patients subjected to severe immunosuppression.
14,34-36 However, in HIV-infected patients with CD4+ T cell counts under 50/mm 3 we observed lower levels of circulating PBMC-EBV, which counters the findings of Dehee et al. who found increased PBMC-EBV DNA levels even in this group (<50 LT CD4+/mm 3 ). 19 Our observations could be explained if we consider that copies of peripheral EBV have been detected only in memory B lymphocytes, 37,38 cells generated after a germinal center reaction. 39, 40 Thus, the decline in the PBMC-EBV load could be due to the decrease in circulating memory B lymphocytes observed during HIV infection. 41, 42 This reduction may be due to hyperactivation-induced memory B cell exhaustion, increased apoptosis, on top of an abnormal naïve B cell activation/ differentiation process. 43 Therefore, we conclude that it would be interesting to analyze EBV level variation relative to the quantity of B lymphocytes at different stages of HIV infection.
Like Dehee et al., 19 we found no correlation between total CD8+ Tcell count and PBMC-EBV load. It should be pointed out that van Baarle et al., studying HIV-infected patients, analyzed the EBV-specific CD8+ T cell population (which represents a small proportion of total CD8+ T lymphocytes), and observed a normal number, although with decreased functional capacity, compared to HIV negative individuals. 44 Also, our study shows that in HIV-infected patients, the EBV found in peripheral blood is carried mainly in PBMC (cellassociated virus), in agreement with Stevens et al., 23 although our study analyzed a substantially larger number of patients. Moreover, we observed no correlation between PBMC-EBV and plasma-EBV loads, as reported by van Baarle et al. 22 and Righetti et al. 45 Further, the plasma-EBV levels of 176 M.D. Fellner et al. HIV-infected patients without lymphoma were lower or similar to those found in PBMC which could indicate that the EBVplasma load results from the lysis of latently-infected circulating B cells (necrosis or apoptosis), or that peripheral lytic infection (either the presence of circulating EBV-virions and/ or lysis of circulating EBV-activated B cells) is not the main cause of increased circulating EBV, or both. It would be interesting for future studies to establish whether plasma-EBV load corresponds to encapsulated virions or nude viral DNA.
Different authors have described variable circulating EBV DNA levels when lymphoma is diagnosed in HIV-infected patients. 21, 31 Also, prospective studies by van Baarle et al. have shown that HIV-infected patients with non-Hodgkin lymphomas have EBV levels that fluctuate over time, being at the time of lymphoma diagnosis lower, similar to, or higher than those previously detected. 22, 44 Recently, Fan et al. described significantly higher plasma-EBV levels in HIVinfected patients with EBV-associated lymphomas compared to HIV-infected patients with non-EBV-associated lymphomas, or without lymphomas. However, plasma-EBV load varied in the samples collected before, during, and after lymphoma diagnosis, although EBV DNA was detectable at least in one sample. It was noted that in primary brain lymphoma cases, the EBV load was mainly not detectable at the time of diagnosis. 25 In this study, the PBMC-EBV load in AIDS patients with PCNSL (group C-BL) was lower than that found in the initial stages of HIV infection (groups A and B), albeit similar to the levels found in AIDS patients without lymphoma (group C). Further, PBMC-EBV levels were undetectable or low in all patients with PCNSL diagnosis, seeming to indicate that EBV load determination would not be a useful indicator of lymphoma, even though only few cases were analyzed. Since PCNSL is a pathology found in HIV-infected patients with advanced immunological deterioration, our findings could be accounted for, as previously mentioned, by the decrease in memory B lymphocytes, described in the course of HIV infection. Moreover, although most of the lymphoma patients showed undetectable plasma-EBV load, it was higher, even more than PBMC-EBV levels, in two cases, suggesting increased lysis of latently-infected circulating B cells, and/or peripheral lytic infection, at least in some of these patients. In this sense, it would also be interesting to determine whether plasma-EBV load in HIV-infected patients with lymphoma corresponds to virions or to nude DNA.
In conclusion, EBV found in peripheral blood of HIVinfected patients is mainly cell-associated. Also, during the course of HIV infection, when the CD4+ T cell count is above 50/mm 3 , the PBMC-EBV levels are increased, which would reflect the loss of EBV infection control due to progressive immunosuppression. When immunological deterioration progresses and the CD4+ T cell count is below 50/ mm 3 , the PBMC-EBV load decreases; perhaps because of altered B lymphocytes (memory and naïve) distribution, and inappropriate activation/differentiation that have been described in the course of HIV infection. Also, the determination of the PBMC-EBV load in AIDS patients with PCNSL would not be a useful indicator of lymphoma, while the meaning of EBV DNA in these patients' plasma remains to be clarified.
